Rutgers Office for Research’s Innovation Ventures (now Technology Transfer) has executed an exclusive license agreement between the university and Sauvie BiKE, LLC, a subsidiary of Sauvie Inc., to develop and commercialize a bi-specific natural killer cell engager technology in the field of oncology.

Rutgers researchers hope their genome-assembly tool will spur the development of new treatments for bacterial infections.

A Rutgers study shows how digestive inflammation may drive MS and provides further evidence that more fiber by combat the condition.

The Office for Research hosted a well-attended open house for researchers and faculty to tour the newly renovated 30,000 sq. ft. state-of-the-art Research Tower Core Services facility.

Want to get more from holiday get-togethers? A Rutgers psychiatrist has research-based tips.

Scientists from Rutgers University-New Brunswick are leading a new $3.2 million study that aims to continue developing sweet basil plants resistant to downy mildew and an emerging bacteria that has decimated the crops of the culinary herb for more than a decade.

From engineering a strawberry ideal for dipping to developing a biodegradable spray-on alternative to food wrap to tracking where humpback whales hang out along the Jersey Shore, here are the staff picks for 2022’s top research and innovation stories at Rutgers.

Whether it was the discovery that sleep meds may help curb addiction, a warning of a microbiome collapse or the launch of clinical trials for COVID-19 treatments, Rutgers provided crucial research in health sciences. 

The Office for Research is excited to announce that Rutgers Associate Vice President of Innovation Ventures (now Technology Transfer) Tatiana Litvin-Vechnyak has been elected to the AUTM Board of Directors. She will begin her three-year term on February 22, 2023, at the conclusion of AUTM’s annual meeting.

Mice altered to prevent the production of a particular type of immune cell struggled to form new memories.